2.94% 0.0219

Citius Oncology Inc (CTOR)

Überblick Nachrichten Preisverlauf Financials Forum Prognose

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Citius Oncology Inc Stock (CTOR) Company Profile

Citius Oncology Inc

Healthcare (1052)

(908) 967-6677

11 COMMERCE DRIVE, CRANFORD

Nächster Verdiensttermin

Neueste SEC-Einreichungen

CTOR's Discussions on Twitter

Compare CTOR vs TAK, TEVA, HLN, ZTS, UTHR

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
CTOR Citius Oncology Inc	0.7679	81.21M	5.61M	-42.51M	-16.86M	-0.466
TAK Takeda Pharmaceutical Co Adr	19.67	62.84B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	41.50	48.40B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	10.13	44.55B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	79.38	32.80B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	533.12	22.87B	3.17B	1.29B	1.01B	27.09

Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-09-23	Hochstufung	Maxim Group	Hold → Buy
2024-11-27	Eingeleitet	Maxim Group	Buy

Citius Oncology Inc Aktie (CTOR) Neueste Nachrichten

Finanzdaten der Citius Oncology Inc-Aktie (CTOR)

Citius Oncology Inc (CTOR)

Citius Oncology Inc Stock (CTOR) Company Profile

Compare CTOR vs TAK, TEVA, HLN, ZTS, UTHR

Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades

Citius Oncology Inc Aktie (CTOR) Neueste Nachrichten

Citius Oncology Announces Results of 2026 Annual Stockholder Meeting Votes - Kalkine Media

Citius Pharmaceuticals at Moody Capital conference: launch gains traction By Investing.com - Investing.com Canada

Citius Pharmaceuticals at Moody Capital conference: launch gains traction By Investing.com - Investing.com UK

CTXR Stock Price, Quote & Chart - ChartMill

Citius Pharma CEO to speak at two New York conferences - Stock Titan

Citius Pharmaceuticals to Participate in September 2026 Investor Conferences - PR Newswire

CITIUS ONCOLOGY, INC. SEC Filing (Aug 26, 2026) - Stock Titan

Citius (CTOR) Quarterly Results: The EPS Result Is Below Expectation in the Latest Session; Session Move: Shares Finish 2.02% Lower on the DayEPS Surprise History - vinanet.vn

Enterprise value to EBIT forward of Citius Oncology, Inc. – NASDAQ:CTOR - TradingView

Armistice Capital Expands Citius Oncology (CTOR) Stake Despite Distress Signals - GuruFocus

Citius (CTOR) Quarterly Results: Reported EPS Misses Expectations in the Reported Period; After Results: The Market Price Advances 6.97% on the DayForward Guidance Trends - vinanet.vn

Citius Oncology Shares Slide 10% After Fiscal Q3 Revenue Misses Estimates Despite LYMPHIR Launch Gains - dars.gov.et

Citius Oncology shares tumble as Q3 revenue misses forecasts despite LYMPHIR launch momentum - Yahoo Finance

Citius Oncology stock tumbles 10% on revenue miss despite launch progress - Investing.com Australia

Citius Oncology stock tumbles 10% on revenue miss despite launch progress - Investing.com

Citius Oncology stock tumbles 10% on revenue miss despite launch progress - Investing.com

Citius Pharmaceuticals Reports LYMPHIR Revenue Growth, Explores CAR-T Combination - The Clinical Trial Vanguard

CTOR Q2 2026 Earnings: Pre-Revenue Loss Misses Badly, Yet Shares Jump 10%EBITDA Analysis - vinanet.vn

Breakeven On The Horizon For Citius Oncology, Inc. (NASDAQ:CTOR) - simplywall.st

Citius Pharma Reports First LYMPHIR Revenue of $7.1M in Nine Months - minichart.com.sg

Citius Oncology Posts First Revenue from LYMPHIR Launch as Institutional Demand Surges 31% - Minichart

Citius Oncology (NASDAQ:CTOR) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat

Citius Oncology (CTOR) director Jonathan Peri files Form 3 showing no common shares - Stock Titan

Citius Pharma Q3 EPS beats estimate, sales miss by 72% - scanx.trade

Citius Oncology Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Citius Pharmaceuticals Reports Q3 2026 Financial Results and LYMPHIR Progress - Intellectia AI

CTOR: LYMPHIR launch drove $7.1M revenue and 31% sequential vial order growth, with broad payer access - TradingView

Citius Oncology (CTOR) grows LYMPHIR sales but posts $41M nine-month loss - Stock Titan

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update - PR Newswire

Citius Oncology (CTOR) Advances 5.5% to $0.87 as Buyers Defend Support ZoneInverse ETF Flow - vinanet.vn

Citius Oncology (CTOR) investor reports 9.99% beneficial ownership stake - Stock Titan

Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update - PR Newswire

Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update - Yahoo Finance

Citius Oncology (CTOR) Advances 5.5% to $0.87 as Buyers Defend Support ZoneRSI Oversold Picks - siam.in

Citius Oncology (CTOR) Advances 5.5% to $0.87 as Buyers Defend Support ZoneIsland Reversal - dars.gov.et

Citius Pharmaceuticals (CTXR) holders report 3.0M-share, 9.9% beneficial stake - Stock Titan

Citius Oncology appoints independent director Peri to board of directors - ROI-NJ

Citius Oncology appoints Jonathan Peri to board of directors By Investing.com - Investing.com Australia

People on the Move: Jonathan Peri, Ph.D., J.D., Joins Citius Oncology’s Board of Directors - BioBuzz

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri - Morningstar

Citius Pharmaceuticals expands Citius Oncology board to nine with appointment of Jonathan Peri - Traders Union

Form 8K Citius Oncology Inc For: 12 August By Investing.com - Investing.com South Africa

Form 8K Citius Oncology Inc For: 12 August By Investing.com - Investing.com Australia

Form 8K Citius Oncology Inc For: 12 August By Investing.com - Investing.com Canada

Form 8K Citius Oncology Inc For: 12 August By Investing.com - Investing.com Nigeria

Citius Oncology adds independent director to expanded board - TipRanks

Citius Oncology appoints Jonathan Peri to board of directors By Investing.com - Investing.com Nigeria

Citius Oncology appoints Jonathan Peri to board of directors By Investing.com - Investing.com India

Citius Oncology appoints Jonathan Peri to board of directors By Investing.com - Investing.com Australia

Citius Oncology Adds Jonathan Peri to Board as LYMPHIR Commercialization Advances - citybiz

Finanzdaten der Citius Oncology Inc-Aktie (CTOR)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie CTOR